LitAlert ~~ GeneLit.com

    • Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    • Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T.
    • Breast Cancer Res Treat. 2020 Jun 3. doi: 10.1007/s10549-020-05716-0. Epub ahead of print.
    • Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    • Alter BP, Best AF.
    • Breast Cancer Res Treat. 2020 Jun 2. doi: 10.1007/s10549-020-05710-6. Epub ahead of print.
    • Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    • Hirotsu Y, Schmidt-Edelkraut U, Nakagomi H, Sakamoto I, Hartenfeller M, Narang R, Soldatos TG, Kaduthanam S, Wang X, Hettich S, Brock S, Jackson DB, Omata M.
    • Int J Mol Sci. 2020 May 29;21(11):E3895. doi: 10.3390/ijms21113895.
  • LitAlert ~~ GeneLit.com

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • [New advances in targeted therapy for breast cancer].
    • Zhao J, Wu N, Zhang SC, Zhao ZW, Li LJ, Liu JT.
    • Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. Chinese. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
    • Review, [Article in Chinese]
    • Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.
    • Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, Tourpin S, Livera G, Lopez BS, Misrahi M.
    • J Med Genet. 2020 Jun 1:jmedgenet-2019-106672. doi: 10.1136/jmedgenet-2019-106672. Epub ahead of print.
    • Case report
  • LitAlert ~~ GeneLit.com

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • [New advances in targeted therapy for breast cancer].
    • Zhao J, Wu N, Zhang SC, Zhao ZW, Li LJ, Liu JT.
    • Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. Chinese. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
    • Review, [Article in Chinese]
  • LitAlert ~~ GeneLit.com

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.
    • Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, Tourpin S, Livera G, Lopez BS, Misrahi M.
    • J Med Genet. 2020 Jun 1:jmedgenet-2019-106672. doi: 10.1136/jmedgenet-2019-106672. Epub ahead of print.
    • Case report
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
  • LitAlert ~~ GeneLit.com

    • Risk stratification in breast cancer screening: cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
    • Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Broeders MJM, de Koning HJ.
    • Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33126. [Epub ahead of print]
    • Nouvelle stratégie chirurgicale dans les mastectomies bilatérales prophylactiques avec reconstruction par prothèses chez les patientes présentant une mutation du gène BRCA [New surgical strategy in breast reconstruction with implants for bilateral prophylactic mastectomies with BRCA gene mutation].
    • Deveaux C, Calibre C, Duquennoy-Martinot V, Guerreschi P, Dumont A.
    • Ann Chir Plast Esthet. 2020 May 29:S0294-1260(20)30077-7. French. doi: 10.1016/j.anplas.2020.05.004. Epub ahead of print.
    • [Article in French]
  • LitAlert ~~ GeneLit.com

    • Remote Screening Test for Ovarian Cancer Receives Study Validation.
    • [No author given]
    • Clinical OMICs. 2020 Jun 2.
    • Risk stratification in breast cancer screening: cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
    • Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Broeders MJM, de Koning HJ.
    • Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33126. [Epub ahead of print]
    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait.
    • Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, Tourpin S, Livera G, Lopez BS, Misrahi M.
    • J Med Genet. 2020 Jun 1:jmedgenet-2019-106672. doi: 10.1136/jmedgenet-2019-106672. Epub ahead of print.
    • Nouvelle stratégie chirurgicale dans les mastectomies bilatérales prophylactiques avec reconstruction par prothèses chez les patientes présentant une mutation du gène BRCA [New surgical strategy in breast reconstruction with implants for bilateral prophylactic mastectomies with BRCA gene mutation].
    • Deveaux C, Calibre C, Duquennoy-Martinot V, Guerreschi P, Dumont A.
    • Ann Chir Plast Esthet. 2020 May 29:S0294-1260(20)30077-7. French. doi: 10.1016/j.anplas.2020.05.004. Epub ahead of print.
    • [Article in French]
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • [New advances in targeted therapy for breast cancer].
    • Zhao J, Wu N, Zhang SC, Zhao ZW, Li LJ, Liu JT.
    • Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. Chinese. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
    • Review, [Article in Chinese]
  • LitAlert ~~ GeneLit.com

    • Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 1.

    Drug Approval: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (U.S. Food & Drug Administration)

    • Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers.
    • Anderson A.
    • Precision Oncology News. 2020 May 31.
    • Olaparib Makes OS Gains in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2020 May 29. doi: 10.1158/2159-8290.CD-NB2020-048. Epub ahead of print.
    • News
    • Ancestry-specific predisposing germline variants in cancer.
    • Oak N, Cherniack AD, Mashl RJ; TCGA Analysis Network, Hirsch FR, Ding L, Beroukhim R, Gümüs ZH, Plon SE, Huang KL.
    • Genome Med. 2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3.
    • Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    • Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.
    • Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.
    • Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.
    • Int J Mol Sci. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 May 21:S1879-8500(20)30099-0. doi: 10.1016/j.prro.2020.04.003. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.